RxDoctor Payments Data

Bradley Rue, MD

Internal Medicine · Sherman, TXNPI 1508835471

Payments from drug & device makers

$1,519in general payments, 2019–2025

Across 95 payments — averaging $15.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$151
  • Johnson & Johnson$125
  • Merck$122
  • AstraZeneca$121
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$118
  • Lilly USA, LLC$116
  • plus $766 from 18 others

What the payments were for

  • Food & beverage$1,519100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,519 in reported general payments places this provider in the 70th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$231,778
Medicare patients
440
Services billed
5,164

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide189$214,584
EliquisApixaban179$155,033
MounjaroTirzepatide92$112,115
JardianceEmpagliflozin87$85,771
Trelegy ElliptaFluticasone/Umeclidin/Vilanter94$79,156
JanuviaSitagliptin Phosphate80$55,976
FarxigaDapagliflozin Propanediol69$52,411
XareltoRivaroxaban73$48,527
TrulicityDulaglutide39$37,428
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog28$26,115
Repatha SureclickEvolocumab43$23,037
MyrbetriqMirabegron29$21,406
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog31$15,622
Breo ElliptaFluticasone/Vilanterol13$14,197
LinzessLinaclotide27$14,083

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$106$214,584189 claims
PfizerEliquis, Premarin$66$163,510191 claims
Lilly USA, LLCMounjaro, Trulicity$116$149,542131 claims
GSKTrelegy Ellipta, Breo Ellipta$15$93,353107 claims
Boehringer IngelheimJardiance$85$85,77187 claims
MerckJanuvia, Belsomra$122$61,09192 claims
AstraZenecaFarxiga, Symbicort$121$59,34699 claims
Johnson & JohnsonXarelto$125$48,52773 claims
AbbVieLinzess, Synthroid$151$21,170150 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Sherman

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →